JP2023033129A5 - - Google Patents

Download PDF

Info

Publication number
JP2023033129A5
JP2023033129A5 JP2022113835A JP2022113835A JP2023033129A5 JP 2023033129 A5 JP2023033129 A5 JP 2023033129A5 JP 2022113835 A JP2022113835 A JP 2022113835A JP 2022113835 A JP2022113835 A JP 2022113835A JP 2023033129 A5 JP2023033129 A5 JP 2023033129A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutically acceptable
formula
narcolepsy
mchr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022113835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023033129A (ja
Filing date
Publication date
Priority claimed from PCT/US2021/012869 external-priority patent/WO2021142395A1/en
Application filed filed Critical
Publication of JP2023033129A publication Critical patent/JP2023033129A/ja
Publication of JP2023033129A5 publication Critical patent/JP2023033129A5/ja
Priority to JP2025094423A priority Critical patent/JP2025120306A/ja
Pending legal-status Critical Current

Links

JP2022113835A 2020-01-10 2022-07-15 薬物の治療的組み合わせ及びそれらの使用方法 Pending JP2023033129A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025094423A JP2025120306A (ja) 2020-01-10 2025-06-05 薬物の治療的組み合わせ及びそれらの使用方法

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202062959769P 2020-01-10 2020-01-10
US202062959534P 2020-01-10 2020-01-10
US62/959,769 2020-01-10
US62/959,534 2020-01-10
US202062980053P 2020-02-21 2020-02-21
US62/980,053 2020-02-21
US202063022484P 2020-05-09 2020-05-09
US63/022,484 2020-05-09
PCT/US2021/012869 WO2021142395A1 (en) 2020-01-10 2021-01-10 Therapeutic combinations of drugs and methods of using them
JP2022542390A JP2023509800A (ja) 2020-01-10 2021-01-10 薬物の治療的組み合わせ及びそれらの使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022542390A Division JP2023509800A (ja) 2020-01-10 2021-01-10 薬物の治療的組み合わせ及びそれらの使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025094423A Division JP2025120306A (ja) 2020-01-10 2025-06-05 薬物の治療的組み合わせ及びそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2023033129A JP2023033129A (ja) 2023-03-09
JP2023033129A5 true JP2023033129A5 (cg-RX-API-DMAC10.html) 2024-01-18

Family

ID=76788320

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022542390A Pending JP2023509800A (ja) 2020-01-10 2021-01-10 薬物の治療的組み合わせ及びそれらの使用方法
JP2022113835A Pending JP2023033129A (ja) 2020-01-10 2022-07-15 薬物の治療的組み合わせ及びそれらの使用方法
JP2025094423A Pending JP2025120306A (ja) 2020-01-10 2025-06-05 薬物の治療的組み合わせ及びそれらの使用方法
JP2025114768A Pending JP2025137534A (ja) 2020-01-10 2025-07-07 薬物の治療的組み合わせ及びそれらの使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022542390A Pending JP2023509800A (ja) 2020-01-10 2021-01-10 薬物の治療的組み合わせ及びそれらの使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025094423A Pending JP2025120306A (ja) 2020-01-10 2025-06-05 薬物の治療的組み合わせ及びそれらの使用方法
JP2025114768A Pending JP2025137534A (ja) 2020-01-10 2025-07-07 薬物の治療的組み合わせ及びそれらの使用方法

Country Status (6)

Country Link
US (2) US20230084144A1 (cg-RX-API-DMAC10.html)
EP (2) EP4151210A3 (cg-RX-API-DMAC10.html)
JP (4) JP2023509800A (cg-RX-API-DMAC10.html)
CN (3) CN115350184A (cg-RX-API-DMAC10.html)
AU (1) AU2021206286A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021142395A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP2200222A1 (hu) * 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére
CN119925562B (zh) * 2023-11-03 2025-11-28 中国科学院上海药物研究所 趋化因子受体2拮抗剂在制备治疗糖尿病并发焦虑症的应用
CN117379427A (zh) * 2023-11-08 2024-01-12 厦门市儿童医院(复旦大学附属儿科医院厦门医院) 化合物THBXM在制备THR-β激动剂中的应用
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
EP1368006B1 (en) 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US6809104B2 (en) * 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US9044381B2 (en) 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
JP2007509158A (ja) * 2003-10-23 2007-04-12 グラクソ グループ リミテッド 肥満、糖尿病、うつ病及び不安を治療するためのmchr1アンタゴニストとしての3−(4−アミノフェニル)チエノピリミド−4−オン誘導体
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
PE20080150A1 (es) * 2006-06-02 2008-04-11 Janssen Pharmaceutica Nv Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
ES2483866T3 (es) * 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
SG178716A1 (en) * 2007-01-16 2012-03-29 Ipintl Llc Novel composition for treating metabolic syndrome
WO2008144305A1 (en) * 2007-05-18 2008-11-27 Janssen Pharmaceutica N.V. Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
CA2727055C (en) * 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
CN102595902B (zh) * 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
JP5739415B2 (ja) * 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー (S)−7−([1,2,4]トリアゾロ[1,5−a]ピリジン−6−イル)−4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロイソキノリンの結晶形態およびその使用
ES2446971T3 (es) * 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
SG178880A1 (en) * 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2013180149A1 (ja) * 2012-05-30 2013-12-05 富山化学工業株式会社 重水素化含窒素複素環カルボキサミド誘導体またはその塩
WO2014039412A1 (en) * 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
US20140364367A1 (en) * 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
US20190060301A1 (en) * 2016-01-15 2019-02-28 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
WO2020144146A1 (en) * 2019-01-07 2020-07-16 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients

Similar Documents

Publication Publication Date Title
JP3432823B2 (ja) 新規の有効な末端分化誘発剤およびその使用方法
RU2186763C2 (ru) Амидные производные или их соли
JP2022120072A (ja) ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用
US9676708B2 (en) Controlled HNO release through intramolecular cyclization-elimination
JP3179599B2 (ja) 縮合ベンゼンオキシ酢酸誘導体およびそれらを有効成分として含有する薬剤
EA002763B1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
US20050165114A1 (en) Benzene derivatives and pharmaceutical use thereof
JP6363164B2 (ja) ヒストンデアセチラーゼ阻害剤及びその組成物と使用方法
JP2016513076A5 (cg-RX-API-DMAC10.html)
EA026702B1 (ru) Производные анилина, их получение и терапевтическое применение
KR100629628B1 (ko) 치환된 2-벤질아미노-2-페닐-아세트아미드 화합물 및 이를 포함하는 약제학적 조성물
US20210363110A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
JP3542599B2 (ja) 置換(アリールアルコキシベンジル)アミノプロパンアミド誘導体及びその製造方法
AU2023236147A1 (en) Ralinepag prodrugs and uses thereof
US20050032747A1 (en) COX-2 and FAAH inhibitors
CN110372593A (zh) 大麻素受体拮抗剂/反向激动剂
JP2025526464A (ja) 血漿カリクレインの阻害剤
JP2002514621A (ja) 置換グアニジン及びジアミノニトロエテン、それらの製造及び使用
US20050288369A1 (en) Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same
JP2004534776A (ja) Cox−2選択的阻害剤としてのピリミジン誘導体
TW201341365A (zh) 作用於多種前列腺素受體從而提供一般抗發炎反應之化合物
US20080261981A1 (en) Novel derivatives of amino acids for treatment of obesity and related disorders
CA2538072C (en) Amide-type carboxamide derivatives
CN1173697C (zh) 用于治疗过敏性疾病的苯胺二硫化物衍生物
JP2004532264A (ja) ピリミジン誘導体